JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Journal of Neurology, Neurosurgery, and Psychiatry 2006;77:781-783; doi:10.1136/jnnp.2005.083345
Copyright © 2006 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Read responses to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brandt-Christensen, M
Right arrow Articles by Kessing, L V
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brandt-Christensen, M
Right arrow Articles by Kessing, L V

SHORT REPORT

Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: a pharmacoepidemiological study

M Brandt-Christensen1, K Kvist2, F M Nilsson3, P K Andersen2, L V Kessing1

1 Department of Psychiatry, University Hospital of Copenhagen, Rigshospitalet, Denmark
2 Department of Biostatistics, University of Copenhagen, Denmark
3 Department of Psychiatry, University Hospital of Copenhagen, Amager, Denmark

Correspondence to:
Correspondence to:
Dr M Brandt-Christensen
Department of Psychiatry, University of Copenhagen, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen, Denmark; mette.brandt{at}rh.dk


ABSTRACT
Objective: To estimate the risk for persons treated with antidepressants or lithium of subsequent treatment with antiparkinson drugs (APD).

Methods: The Danish national prescription database supplied data on all persons who received antidepressants, lithium, or antidiabetics (first control group). A second control group was included comprising persons from the general population. Outcome was purchase of APD and the study period was 1995 to 1999.

Results: In total, 1 293 789 persons were included. The rate ratio of treatment with APD after treatment with antidepressants was 2.27 (95% CI 2.14 to 2.42) for men and 1.50 (95% CI 1.43 to 1.58) for women. Figures for lithium were almost identical.

Conclusion: Persons treated with antidepressants or lithium are at increased risk of subsequently treatment with APD, showing an association between anxiety/affective disorder and Parkinson’s disease.

Abbreviations: APD, antiparkinson drugs; PD, Parkinson’s disease; ATC, anatomical therapeutic classification; RR, rate ratio

Keywords: affective disorder; Parkinson’s disease; pharmacoepidemiology




eLetters:

Read all eLetters

An alternative explanation for increased antiparkinson medications with lithium or antidepressants
Joseph H Friedman, et al.
JNNP Online, 23 May 2006 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd.